Bank of Montreal Can Sells 8,750 Shares of Amedisys, Inc. (NASDAQ:AMED)

Bank of Montreal Can lowered its position in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 66.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,343 shares of the health services provider's stock after selling 8,750 shares during the quarter. Bank of Montreal Can's holdings in Amedisys were worth $394,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of AMED. Norges Bank acquired a new stake in Amedisys during the 4th quarter worth about $83,061,000. Wealthfront Advisers LLC acquired a new stake in shares of Amedisys in the fourth quarter worth $72,970,000. Pacer Advisors Inc. increased its position in Amedisys by 11,621.9% during the fourth quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider's stock worth $50,679,000 after acquiring an additional 553,435 shares during the period. Birnam Oak Advisors LP bought a new position in Amedisys during the fourth quarter worth $15,832,000. Finally, Calamos Advisors LLC increased its position in Amedisys by 22.7% during the fourth quarter. Calamos Advisors LLC now owns 487,444 shares of the health services provider's stock worth $44,255,000 after acquiring an additional 90,097 shares during the period. Institutional investors own 94.36% of the company's stock.

Amedisys Trading Up 0.2 %

Shares of NASDAQ AMED traded up $0.19 during trading on Monday, reaching $94.69. The company had a trading volume of 295,185 shares, compared to its average volume of 406,180. The company's fifty day moving average price is $92.25 and its 200-day moving average price is $91.74. Amedisys, Inc. has a 12 month low of $82.15 and a 12 month high of $98.95. The stock has a market cap of $3.11 billion, a P/E ratio of 37.58, a PEG ratio of 1.78 and a beta of 0.89. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, beating the consensus estimate of $1.13 by $0.12. The company had revenue of $594.78 million for the quarter, compared to analyst estimates of $597.43 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm's revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.03 EPS. As a group, research analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AMED has been the topic of several analyst reports. Stephens reaffirmed an "equal weight" rating and issued a $101.00 target price on shares of Amedisys in a report on Tuesday, March 4th. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 price target on shares of Amedisys in a research report on Wednesday, April 16th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Amedisys currently has a consensus rating of "Hold" and a consensus target price of $100.75.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.